{
    "id": 24370,
    "fullName": "ABL1 R332W",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ABL1 R332W (corresponding to R351W in isoform IB) lies within the protein kinase domain of the Abl1 protein (UniProt.org). R332W results in increased Abl1 kinase activity, as demonstrated by modest increase in CRKL phosphorylation, and increased cytoplasmic retention of Abl1 in cell culture (PMID: 26758680).",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 25,
        "geneSymbol": "ABL1",
        "terms": [
            "ABL1",
            "ABL",
            "BCR-ABL",
            "bcr/abl",
            "c-ABL",
            "c-ABL1",
            "CHDSKM",
            "JTK7",
            "p150",
            "v-abl"
        ]
    },
    "variant": "R332W",
    "createDate": "07/14/2016",
    "updateDate": "09/06/2018",
    "referenceTranscriptCoordinates": {
        "id": 119218,
        "transcript": "NM_005157",
        "gDna": "chr9:g.130872946C>T",
        "cDna": "c.994C>T",
        "protein": "p.R332W",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7334,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).",
            "molecularProfile": {
                "id": 25102,
                "profileName": "ABL1 R332W"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7337,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).",
            "molecularProfile": {
                "id": 25102,
                "profileName": "ABL1 R332W"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7336,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680).",
            "molecularProfile": {
                "id": 25103,
                "profileName": "ABL1 T315I ABL1 R332W"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7339,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680).",
            "molecularProfile": {
                "id": 25103,
                "profileName": "ABL1 T315I ABL1 R332W"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6310,
                    "pubMedId": 26758680,
                    "title": "Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26758680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 25102,
            "profileName": "ABL1 R332W",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25103,
            "profileName": "ABL1 T315I ABL1 R332W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119218,
            "transcript": "NM_005157",
            "gDna": "chr9:g.130872946C>T",
            "cDna": "c.994C>T",
            "protein": "p.R332W",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}